GLP-1s After 65: 10 Studies, and Not One Designed for Older Adults

10 papers · each one re-checked on PubMed · last verified November 2026

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

Prescribing in this age group is expanding faster than the evidence supporting it. Not one trial below was designed for older adults. The efficacy and safety picture comes from pre-specified and post hoc age strata inside trials built for heart failure, cardiovascular events and glucose. That picture is reassuring. Benefit and tolerability hold up in the oldest participants enrolled. But 'the oldest participants enrolled' is doing real work in that sentence. Trials recruit healthier older people than clinics treat, and the specific hazard clinicians raise is the one no cardiovascular trial measures: in someone already low on muscle, losing a quarter of their weight as lean tissue is a different event than it is at 45. That argument runs through the second half of this list. It is an argument, not a finding, because nobody has run the trial.

Ranked papers

#1STEP-HFpEF (age subgroup)

Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme

Pandey A, Moroney M, Verma S, et al. · Eur J Heart Fail · 2025

What it measured: Symptom scores, walking distance and weight, split by age band

The strongest age evidence available: a pre-specified pooled analysis of the two STEP-HFpEF trials, splitting 1,145 adults with obesity-related heart failure into four age bands, from under 55 to 75 and over (292 people). Symptom scores, six-minute walk distance and weight improved consistently in all four bands, and the safety profile did not shift with age. It is currently the only randomized evidence of this quality in people over 75, the group most often in question.

PMID 41290376 ↗DOI 10.1002/ejhf.70049 ↗

#2SUSTAIN 6 + PIONEER 6 (age subgroup)

Cardiovascular, Metabolic, and Safety Outcomes with Semaglutide by Baseline Age: Post Hoc Analysis of SUSTAIN 6 and PIONEER 6

Bain SC, Belmar N, Hoff ST, et al. · Diabetes Ther · 2025

What it measured: Cardiac events, blood sugar, weight and side effects, split by age band

The two semaglutide cardiovascular safety trials (injectable and oral), pooled and re-cut by baseline age across 6,480 participants with type 2 diabetes. Cardiovascular event reduction and weight loss ran broadly parallel across the age bands, with no excess serious adverse events in the oldest. A1C was the exception: it fell further, relative to placebo, in people 60 and under than in the older groups. It is post hoc rather than pre-specified, which is weaker footing, but it remains the most careful age-stratified safety read in the cardiovascular literature for this drug.

PMID 39520501 ↗DOI 10.1007/s13300-024-01659-7 ↗

#3

Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Use in Elderly People With Obesity: A Meta-Analysis

Rego de Figueiredo I, Simas FS, Ghiletchi A, et al. · Obesity (Silver Spring) · 2026

What it measured: Weight, blood sugar and side effects pooled in adults 65 and over

A meta-analysis of five randomized and observational studies (1,229 participants) comparing adults 65 and over with younger adults. Weight and glucose effects came out comparable, and serious adverse events did not differ. What shifted with age was the mix of side effects. Older adults trended toward less nausea but had more constipation and more hypoglycemia.

PMID 41640092 ↗DOI 10.1002/oby.70098 ↗

#4

Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults: A Systematic Review and Meta-Analysis

Alexander GC, Xiao X, Dilek S, et al. · JAMA Intern Med · 2026

What it measured: Whether weight loss differs by age, sex, race or starting BMI

A systematic review asking whether these drugs work differently across demographic groups, age included. It found no significant difference in weight loss by age (seven trials, 4,314 patients), or by race, ethnicity, starting BMI or A1C. The one difference was sex: women lost more than men (10.9% against 6.8%).

PMID 41770554 ↗DOI 10.1001/jamainternmed.2025.8222 ↗

#5

Weighing the risk of GLP-1 treatment in older adults: Should we be concerned about sarcopenic obesity?

Prokopidis K, Daly RM, Suetta C · J Nutr Health Aging · 2025

What it measured: A review of muscle-loss risk in older patients — not a trial

The clearest statement of a risk the trials never see, because it comes after stopping. Up to two-thirds of users quit within a year and up to half restart, and stopping usually brings the weight back. The authors argue that this cycle of loss and regain can add fat while costing muscle, which puts older adults at risk of sarcopenic obesity, a condition already present in 10 to 20% of them. It is a mini-review that calls for awareness and preventive strategies, not a study that measured the effect.

PMID 40819408 ↗DOI 10.1016/j.jnha.2025.100652 ↗

#6

Treating Sarcopenic Obesity in the Era of Incretin Therapies: Perspectives and Challenges

Chen AS, Batsis JA · Diabetes · 2025

What it measured: A proposed approach to screening older patients before starting — not a trial

A perspective piece that does something the trial literature does not: propose a concrete procedure. It calls for a thorough check of physical function when an incretin is started: screening older adults for sarcopenic obesity (age over 70 is one of the flags) and, where that is suspected, testing grip strength or a timed up-and-go and estimating muscle mass by DXA or bioimpedance. It frames the decision as a trade rather than a yes-or-no. It is a proposal, not a validated protocol; no trial has tested whether screening this way improves outcomes.

PMID 40644314 ↗DOI 10.2337/dbi25-0004 ↗

#7

GLP-1-derived therapies and sarcopenia: plea for a specific focus on at risk special populations

Scheen AJ · Diabetes Metab · 2026

What it measured: An argument about which populations face real muscle-loss risk — not a trial

A short review that names the groups where lean-mass loss most plausibly crosses from a talking point into harm: older people with type 2 diabetes, heart disease, heart failure, kidney disease or fatty liver disease, especially advanced heart failure or kidney disease. It finds no evidence-based demonstration of a raised sarcopenia risk so far and calls for dedicated studies that measure muscle in these groups. It adds no new data.

PMID 41101588 ↗DOI 10.1016/j.diabet.2025.101708 ↗

#8

A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass

Moscucci F, Baratta F, Pastori D, et al. · Nutrients · 2026

What it measured: A review focused on older and postmenopausal women — not a trial

A review focused on postmenopausal and older women, who make up a disproportionate share of Medicare-age prescriptions and are underrepresented in the discussion. It covers how body composition responds differently by sex, how bone loss after estrogen decline interacts with weight loss, and a structured protein-and-training protocol intended to limit lean-mass loss. It is narrative rather than systematic, and the most directly practical entry here for that patient.

PMID 41754149 ↗DOI 10.3390/nu18040632 ↗

#9

Geriatric Pharmacotherapy Case Series: GLP-1 RA for Weight Management in Older Adults

Toma L, Buckley K, Early N · Sr Care Pharm · 2026

What it measured: Case-based pharmacotherapy review

A single teaching case from a geriatric pharmacotherapy series: a 69-year-old man with type 2 diabetes, coronary disease, heart failure with reduced ejection fraction and a rising creatinine who starts semaglutide. It works through problems that come up in geriatric practice and appear in no trial, including several conditions at once, kidney function, muscle loss and cost. Its practical advice is protein intake and regular resistance training to preserve muscle.

PMID 41966038 ↗DOI 10.4140/TCP.n.2026.78 ↗

#10SELECT (hospitalizations analysis)

Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical Trial

Nicholls SJ, Ryan DH, Deanfield J, et al. · JAMA Cardiol · 2026

What it measured: All-cause and cause-specific hospitalizations

An exploratory analysis of SELECT counting hospitalizations rather than cardiac events across its 17,604 participants, all with overweight or obesity plus existing heart disease and about 38% of them 65 or over. Semaglutide reduced all-cause admissions by about 10% and cut days spent in hospital, with no difference in the effect by age. It is exploratory, so treat it as a signal. It matters mostly because hospitalization is the endpoint payers and health systems price coverage against, which makes it a policy document as much as a clinical one.

PMID 41433034 ↗NCT03574597 ↗DOI 10.1001/jamacardio.2025.4824 ↗

About this list

Obesity medicine throws up the same handful of questions over and over, and we answer them with ranked lists anchored to the papers themselves. On 2026-11-10 every citation below was put back through PubMed. Where a trial has a registry entry, the card carries that link too, alongside the PubMed one.

Browse our full index of research lists or our long-form research articles.